Skip to content
Peptigraph home

Hexarelin vs Sermorelin: What the Research Shows

Hexarelin and Sermorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Growth hormone releasing peptide (GHRP)Not FDA approved · research chemicalHexarelinSynthetic analog of ghrelin that binds the growth hormone secretagogue receptor; reviews describe strong growth hormone-releasing effects for this drug class.[12]
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[13]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider Hexarelin if…

  • you want a human GH-release study: hexarelin stimulated GH secretion in patients with idiopathic GH deficiency[14]
  • you are tested in sport and want to avoid a WADA-prohibited substance: WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin (check hexarelin's own status separately)[1]

Consider Sermorelin if…

  • you want human data in growth-hormone-deficient children, though uncontrolled: Mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr at 6 months and 7.2 cm/yr at 12 months (open-label, no control group).[13]

What they have in common

  • A physiology study in normal short children looked at GH responses to GHRH and to hexarelin; it is not a treatment trial[11]
  • Sermorelin's only FDA record is Geref, listed with marketing status Discontinued[15]
Neither is FDA approved for any use in people. Sermorelin is prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 8 of 10 fields where the two differ. Also called, PCAC vote, Jul 2026 are the same or both unknown.

FieldHexarelinSermorelin
ClassGrowth hormone releasing peptide (GHRP)GHRH analog
FDA statusNot FDA approved · research chemicalCompounded by prescription
WADANo WADA record in our dataProhibited by WADA (S2.2.4)Sermorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Anti-doping detectionNone reportedanti-doping literature, as of 2 Oct 2026
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-life[half-life by route]No published half-life foundPubMed search, 11 Oct 2026
Evidence strength[evidence grade]Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 1992, PMID 1379256
Human studies we summarised[n]6 human (1 randomized or controlled) of 9 summarised
Typical study doses[dose range]

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Both appear mainly in GH-response testing, not treatment trials

One cached study puts GHRH and hexarelin in the same experiment: a physiology study, not a treatment trial, in normal short children.[11]

In that study, GH response to GHRH was inhibited after rhGH administration, and rhGH also blunted the response to hexarelin.[11]

Hexarelin's human GH-deficiency study used an intravenous challenge: in idiopathic GH deficiency the GH response to hexarelin was significantly higher than the response to GHRH.[14]

In patients with hypothalamic-pituitary disconnection, the GH response to hexarelin was absent or blunted, which the authors take as evidence that the effect is mediated by the hypothalamus.[14]

Practical differences

Hexarelin administration caused a slight but significant rise in cortisol in the GH-deficient patients without ACTH deficiency.[14]

A metabolism paper says that, with the exemption of GHRP-2, these growth hormone releasing peptides are nonapproved pharmaceuticals that are readily available through internet providers.[17]

Sermorelin, by contrast, has an FDA history: Geref was marketed, and the cached review reports it was discontinued by its sole US maker.[18]

Common questions

Hexarelin vs sermorelin: which is better for GH?

The only studies compare their GH responses in children as separate tests. In idiopathic GH deficiency, hexarelin's GH response was significantly higher than the response to GHRH.[14]

Has hexarelin been used as a treatment like sermorelin?

Hexarelin's human evidence in the cache is a challenge test of GH release in patients with idiopathic GHD.[14]

Do hexarelin and sermorelin work the same way?

Hexarelin is a peptidyl GH secretagogue, and sermorelin is a GHRH analogue. The one study that tested GHRH and hexarelin together was in children, where rhGH blunted the response to both.[11]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  3. 3Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  4. 4Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  5. 5Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  6. 6Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  7. 7PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (hexarelin[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11The negative GH auto-feedback in childhood: effects of rhGH and/or GHRH on the somatotroph response to GHRH or hexarelin, a peptidyl GH secretagogue, in children.Journal of endocrinological investigation · 2000PMID 10803472Accessed 2 Oct 2026
  12. 12Implications of ghrelin and hexarelin in diabetes and diabetes-associated heart diseases.Endocrine · 2015PMID 25645463Accessed 2 Oct 2026
  13. 13Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  14. 14The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.The Journal of clinical endocrinology and metabolism · 1995PMID 7673411Accessed 2 Oct 2026
  15. 15Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  16. 16PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17Metabolism of growth hormone releasing peptides.Analytical chemistry · 2012PMID 23101768Accessed 2 Oct 2026
  18. 18Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026

Found an error? Report a correction.